Including methods for mass production of high-functionality 바카라 cells and related technologies
[by Yu, Suin] Vaxcellbio announced on April 22 the final registration of its original patent in Korea, covering its proprietary natural killer (NK) cell manufacturing technology and therapeutic application for the treatment of liver cancer.
The patent encompasses a manufacturing method capable of mass-producing highly functional 바카라 cells with superior cytotoxic activity against tumor cells, along with a targeted therapeutic strategy for liver cancer treatment using these cells. Central to this technology is the selective proliferation of 바카라 cells achieved by culturing ‘peripheral blood mononuclear cells’ under specific conditions.
This technology is currently being applied to ‘VCB-1102 (development code),’ a Vax-NK treatment candidate positioned as one of 바카라’s core pipeline assets. According to the company, VCB-1102 is an autologous NK cell-based immunotherapy that has demonstrated high therapeutic efficacy. In a Phase 2a clinical trial targeting advanced hepatocellular carcinoma (HCC), the treatment achieved a complete response (CR) rate of 36.4% and an objective response rate (ORR) of 63.6%.
This technology is anticipated to hold significant potential for broad therapeutic application beyond liver cancer, extending to various solid tumors, by enabling the production of 바카라 cells with superior purity and functional activity compared to conventional methods. Moreover, it is expected to dramatically improve treatment efficiency by enhancing resistance to the immunosuppressive tumor microenvironment and increasing the cytotoxic capabilities of 바카라 cells against target cancer cells.
To broaden the therapeutic indications of VCB-1102, 바카라 has obtained approval to conduct advanced regenerative medicine clinical trials for small cell lung cancer, which are currently underway. More recently, the company also secured approval for advanced regenerative clinical trials targeting advanced pancreatic cancer.
“The registration of this patent represents a significant milestone that validates our technological capabilities and originality in the field of NK cell-based immunotherapy,” said Lee Je-jung, CEO of 바카라. “This achievement will serve as an important foundation for the mid- to long-term commercialization and strengthening of competitive advantages of key platforms like VCB-1102.”
With the patent registration, the total number of patents held by 바카라 has increased to 13. These patents encompass advanced technologies in the areas of NK cells, CAR, cultured accessory cells, and canine interleukin-15. In addition, 바카라 is actively expanding its patent portfolio, with six patent applications currently underway, focusing on bone marrow-infiltrating lymphocytes and dual-target CAR-T therapeutics.